Arhalofenate

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameArhalofenate
Drug Alias Name阿洛芬酯arhalofenato阿卤芬酯arhalofenatumMetaglidasen +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor γ modulators
TargetsPeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsHyperuricemiaDiabetes Mellitus, Type 2Gout
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGeorgia +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesCymabay Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKowa Pharmaceuticals America IncXian Janssen Pharmaceutical LtdCymabay Therapeutics Inc +[5] 
Active IndicationsN/A
Inactive IndicationsHyperuricemiaDiabetes Mellitus, Type 2Gout

Other Information

ATC CodeN/A
Related LinksKEGG